Celularity Regains Nasdaq Reporting Compliance After Filing Q2 2026 10-Q
Nasdaq closed Celularity’s periodic reporting deficiency after the company filed its Q2 2026 Form 10-Q on Oct. 20. Previously identified bid-price and market-value deficiencies had also been closed.